Analyses reveal single standard dose efficacy from day 22 to day 90 post vaccination of 76% with protection not falling in this three-month period. After the second dose vaccine efficacy from two standard doses is 82.4% with the 3-month interval being used in the UK (82.4% effective, with a 95% confidence interval of 62.7% - 91.7% at 12+ weeks). Data supports the 4-12 week prime-boost dosing interval recommended by many global regulators. Analyses of PCR positive swabs in UK population suggests vaccine may have substantial effect on transmission of the virus with 67% reduction in positive swabs among those vaccinated.
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Researchers at the University of Oxford have today published in Preprints with The Lancet an analysis of further data from the ongoing trials of the vaccine. In this, they reveal that the vaccine efficacy is higher at longer prime-boost intervals, and that a single dose of the vaccine is 76% effective from 22- to up to 90-days post vaccination.
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
At 7.30 am today, dialysis patient Brian Pinker became the very first person to be vaccinated as part of the UK\u2019s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, with patients at the Oxford University NHS Hospitals Trust becoming the first to receive this life-saving vaccine.
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
Today, researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions.
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build immunity.
The University of Oxford has secured a critical professorship in vaccinology for the future following a gift of \u00a33.33 million from the Sa\u00efd family. The gift will enable Professor Sarah Gilbert, the inaugural post holder, to continue her ground-breaking research in the field, while also helping to ensure that Oxford remains at the forefront of vaccine development for generations to come.
Bvlgari and the University of Oxford\u2019s Jenner Institute announce the next stage of their pledge to build a pandemic-free future by awarding the inaugural Bvlgari Scholarships.
On Friday 18 September, Prime Minister Boris Johnson visited the Old Road Campus Research Building to meet senior researchers from the Medical Sciences Division. The Prime Minister heard about the developments, success and challenges at Oxford in relation to the University\u2019s ongoing COVID-19 research.
A new arm of the ongoing global clinical trials of the ChAdOx1 nCoV-19 vaccine led by AstraZeneca has launched in the US to assess safety, efficacy and immunogenicity of the vaccine for the prevention of COVID-19.
The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
The Phase 1 data shows that the vaccine raised no safety concerns, did not lead to any unexpected symptoms in those who received it, and was very similar to other vaccines of this type.
A generous gift of \u00a33.5 million from Lakshmi Mittal and his family has secured the future of a critical professorship in vaccinology at the University. The post, which is currently held by Professor Adrian Hill, will be known as the Lakshmi Mittal and Family Professorship of Vaccinology in recognition of this support.
Volunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin America\u2019s first phase 3 COVID-19 clinical trial. The trial officially began on Saturday 20th June and will enrol 5,000 volunteers across the country. Vaccinations will take place in Sao Paulo, Rio de Janeiro and a site in the Northeast of Brazil. The Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials on 2nd June, which are being conducted in partnership with AstraZeneca.
The Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway. During his visit, The Duke was briefed about the Group\u2019s work by Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford, who is leading the clinical trial team.
Prof Sarah Gilbert from the Jenner Institute is speaking at a video linked Global Covid-19 vaccine congress on Monday 21st June 2020 organised by the International Society for Vaccines. The\u00a0congress\u00a0is\u00a0free\u00a0to scientists with\u00a0an\u00a0interest\u00a0in\u00a0COVID\u201019\u00a0vaccines (pre\u2010registration\u00a0required).
![\"Bvlgari](\"https://www.jenner.ac.uk/about/news/university-of-oxfords-jenner-institute-appoints-first-bvlgari-scholars/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n